GlassScriptPhysician profile
Azeb Tesfalidet
NPI 1487687521
$507.29
in general payments reported to CMS, 2019-2025
11 companies · $26.06 in 2025
The $26.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $15.22 · 2022: $25.91 · 2023: $89.18 · 2024: $219 · 2025: $26.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $147.10 | 2023-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $75.40 | 2019-2020 | |
| Abbvie INC. | $58.12 | 2022-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $56.29 | 2019 | |
| Merck Sharp & Dohme LLC | $46.12 | 2023-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Boston Scientific Corporation | $32.50 | 2024 | Wavewriter Alpha Prime 16 |
| Daiichi Sankyo INC. | $25.30 | 2024 | Injectafer |
| Amgen INC. | $21.83 | 2024 | Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $15.40 | 2019 | |
| Glaxosmithkline, LLC. | $14.88 | 2023 | Trelegy Ellipta |
| Cranial Technologies, INC | $14.35 | 2024 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azeb Tesfalidet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.